Reuters logo
BRIEF-Active Biotech says CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint
May 8, 2017 / 5:46 AM / 6 months ago

BRIEF-Active Biotech says CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint

STOCKHOLM, May 8 (Reuters) - Active Biotech:

* Teva and Active Biotech today announced results from the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS)

* Says primary endpoint in CONCERTO -- the evaluation of laquinimod versus placebo to evaluate the time to Confirmed Disability Progression (CDP) after at least 3 months - was not met (Reporting by Stockholm Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below